AI-ECG Tracker
Not publicly available
Regulatory Status Disclosed
Overview
AI-ECG Tracker by Shenzhen Carewell Electronics Co. is an artificial intelligence-powered tool designed for the analysis of electrocardiogram (ECG) data. It is primarily intended for use by cardiologists, general practitioners, and other healthcare professionals involved in cardiac care, across various clinical settings including hospitals, clinics, and potentially remote monitoring environments.
- Functionality: The AI-ECG Tracker processes ECG waveforms to assist in the identification of potential cardiac abnormalities. It aims to provide automated preliminary interpretations, which can support clinicians in their diagnostic process.
- Workflow Integration: The tool integrates into a clinical workflow by receiving ECG data, performing its analysis, and then presenting the results for review by a physician. This can potentially streamline the initial screening and interpretation phase of ECG analysis, allowing clinicians to focus on complex cases and final diagnoses.
- Notable Capabilities: Specific capabilities include automated detection of various arrhythmias and other ECG changes. It is designed to enhance the efficiency of ECG interpretation, particularly in scenarios with high volumes of ECGs. The system is built to be compatible with existing ECG acquisition devices, facilitating its adoption into current practice.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered ECG auto-analysis and diagnosis
- High accuracy (over 95%) for common cardiac abnormalities, including arrhythmias, ventricular hypertrophy, myocardial ischemia, and myocardial infarction
- Supports 12-lead ECG data collection
- AI-ECG Workstation with powerful GPU for fast computing
- Web-based Management Portal for organization settings, security, and task management
- Window-based professional ECG diagnostic client for review, measurement, annotation, and report generation
- Rapid diagnosis in approximately 3 seconds
- Comprehensive diagnosis support for 16 cardiac classifications and 104 ECG diagnostic classifications
- Compatible with various ECG data formats (Carewell ECG, HL7 aECG, DICOM ECG, SCP ECG, MFER ECG)
- Customizable professional report generation
Use Cases
- Assisting physicians in ECG analysis and diagnosis in hospitals and clinics
- Improving detection efficiency of non-persistent and transient arrhythmias
- Use in primary medical institutions lacking professional doctors
- Localized and rapid ECG analysis in primary hospitals, private clinics, medical examination centers, community health centers, and pension institutions
- Reducing workload and improving efficiency for professional ECG physicians
- Enabling home ECG monitoring
- Improving ECG analysis and diagnosis for wearable devices
What Physicians Need to Know
ECG/EKG Analysis Capability
Provides automated ECG signal processing and analysis on a beat-by-beat basis, including QRS detection, Supraventricular and Ventricular Ectopic Beat detection, QRS feature extraction, interval measurement, heart rate measurement, and rhythm analysis. It can synchronously collect 12-lead ECG data and supports analysis of data from Holter, event recorders, and 12-lead ambulatory ECG devices. The system offers automated interpretation algorithms to assist physicians in measuring and interpreting ECGs, with results that can be confirmed, edited, or deleted. It detects over 100 ECG abnormalities, including ventricular hypertrophy, myocardial ischemia, and myocardial infarction, with an overall accuracy of up to 98%. Fully-automated analysis generates results in approximately 3 seconds, producing professional and customizable reports.
Arrhythmia Detection Accuracy
Accurately diagnoses arrhythmias, improving the detection efficiency of non-persistent and transient arrhythmias. It specifically detects Supraventricular and Ventricular Ectopic Beats. The platform boasts an overall accuracy of 95% for diagnosing arrhythmias, ventricular hypertrophy, myocardial ischemia, and myocardial infarction, with a reported 98.3% accuracy driven by a deep learning algorithm trained on over 47 million annotated ECG data.
Heart Failure Risk Prediction
The AI-ECG Tracker is intended for the assessment of common cardiac abnormalities, including myocardial infarction and ventricular hypertrophy. While not explicitly a 'heart failure risk prediction' tool, its ability to detect these conditions provides critical information related to heart failure risk and diagnosis.
Cardiac Monitoring Integration
The AI-ECG Platform is hardware-independent, designed to be compatible with almost all existing ECG machines. It supports downloading and analyzing ECG data from various devices like Holter, event recorders, and 12-lead ambulatory ECG devices. Compatible ECG recording formats include Carewell ECG, HL7 aECG, DICOM ECG, SCP ECG, and MFER ECG. Data can be transferred to a local PC via LAN, USB, or other supported protocols, requiring a local wired or wireless network.
AHA/ACC Guideline Alignment
The AI-ECG Tracker has received registration approval from the US Food and Drug Administration (FDA) and obtained certification in the EU. While direct alignment with specific AHA/ACC guidelines is not explicitly stated, its regulatory clearances indicate adherence to established medical device standards.
Real-Time Alert Capability
The AI-ECG Tracker is explicitly stated as not being for use in life-supporting or sustaining systems, or ECG monitoring and alarm devices. Its primary function is for assessment and interpretation rather than real-time alarming.
Physician Tip
The AI-ECG Tracker serves as a powerful auxiliary diagnostic tool, significantly enhancing the speed and accuracy of ECG analysis. Physicians should utilize its automated interpretations as advisory information, always confirming, editing, or modifying results based on their clinical expertise, patient history, symptoms, and other diagnostic data. It is particularly beneficial in settings with limited specialist availability, streamlining the diagnostic process. Note that the tool is intended for adults aged 22 and older without pacemakers and should not be the sole means of diagnosis.
The AI-ECG Platform is designed for broad compatibility, being hardware-independent and able to integrate with most existing ECG machines. It supports various standard ECG data formats (Carewell ECG, HL7 aECG, DICOM ECG, SCP ECG, MFER ECG) for seamless data import. Data acquisition from patient devices can be transferred to a local PC via LAN, USB, or other supported protocols, requiring a local wired or wireless network for operation.
Details
| Category | Cardiology AI |
| Pricing | Not publicly available — Not publicly available |
| Deployment | On-premise (AI-ECG Workstation, Diagnostic Client) with optional cloud service (Lepu Nebula Cloud) for remote diagnostic services. |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated The AI-ECG Tracker received FDA 510(k) premarket notification clearance (K200036) on March 20, 2020. It is intended for use by qualified healthcare professionals in hospitals and healthcare facilities to assist in the assessment of arrhythmias using ECG data from adults (age 22 and older) without pacemakers. |
| Integrations | |
| EHR | Not specified |
| Specialties | Cardiology, Emergency Medicine |
What the Web Says
The AI-ECG Tracker, such as the PMcardio and Wellue devices, is generally viewed as a valuable tool for assisting healthcare professionals in ECG interpretation, particularly in detecting subtle or high-risk cardiac events. Physicians appreciate its potential to improve diagnostic accuracy and streamline workflows, especially in emergency settings or when specialist support is limited. However, it's consistently emphasized that these AI tools should serve as decision support and not replace the clinical judgment of qualified healthcare professionals.
Overall: MixedStrengths
- Improved accuracy in detecting subtle STEMI, STEMI equivalents, and acute occlusion MI.
- Can speed up cath lab activation and treatment for high-grade AV blocks.
- Helpful in situations with limited support or when clinicians are fatigued.
- User-friendly interface and easy to operate.
- Provides professional ECG data reports for forwarding to doctors.
- Offers educational and training opportunities for ECG interpretation.
Limitations
- Not yet FDA-cleared for clinical decision-making (for some models like PMcardio).
- May not detect all conditions, such as certain WPW patterns or hyperkalemia.
- Can be slower than human interpretation due to operational steps like loading images.
- Some devices may have reliability issues, with reports of devices stopping working.
- Lack of a backup channel in case of artifacts and limited functions in the ECG browser for some devices.
- Potential for false positives leading to unnecessary hospital visits and increased clinician fatigue.
Based on reviews from: YouTube, Wellue Health, HealthUnlocked, Capterra, PubMed Central, Reddit, G2, The Skeptical Cardiologist, Carewell
Last updated: 2026-07-21
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate AI-ECG Tracker
Press & Coverage
RadAI Slice
AI-ECG Tracker | FDA Radiology AI Device - X-ray Interpreter
The AI-ECG Tracker, developed by Shenzhen Carewell Electronics Co., Ltd., received FDA approval on March 20, 2020. It is software designed to assist healthcare professionals in analyzing ambulatory ECG data to detect and assess cardiac arrhythmias in adults.
2020-03
NAI 500
Lepu Medical Technology's AI-ECG Tracker Gains US FDA's Seal | NAI 500
Lepu Medical Technology Beijing's AI-ECG Tracker, developed by its Shenzhen Carewell Electronics unit, received FDA approval, marking a global market milestone after its EU certification. The software improves the detection efficiency of non-persistent arrhythmias.
2020-03
MDPI
Artificial Intelligence in Translational Medicine - MDPI
This peer-reviewed article discusses the application of AI in translational medicine, citing the AI-ECG Tracker (Shenzhen Carewell Electronics, Ltd.) as a tool for improving the detection efficiency of non-persistent arrhythmias, with FDA approval in March 2020.
2021-11
Preprints.org
Artificial Intelligence in Translational Medicine - Preprints.org
A preprint publication highlights the AI-ECG Tracker from Shenzhen Carewell Electronics, Ltd., noting its use in improving the detection of non-persistent arrhythmias and its FDA authorization in March 2020.
2021-10
PMC (NIH)
Analysis of Devices Authorized by the FDA for Clinical Decision Support in Critical Care - PMC
This analysis of FDA-authorized devices for clinical decision support in critical care lists the AI-ECG Tracker by Shenzhen Carewell Electronics Co., Ltd., as a device that measures and interprets ECGs, receiving 510(k) premarket notification on March 20, 2020.
2023-10
Medgadget
AI in Cardiology Market Drive US$ 40.5 Billion Growth By 2033
This market report mentions the AI ECG Tracker by Shenzhen Carewell Electronics as one of the AI-based technologies approved by regulatory agencies like the FDA, paving the way for improved cardiovascular disease assessment.
2024-12
Towards Healthcare
AI in Cardiology Market Size Leads 34.38% CAGR by 2034 - Towards Healthcare
This article on the AI in cardiology market trends lists the AI ECG Tracker by Shenzhen Carewell Electronics as an FDA-approved AI/ML-based technology for the detection of arrhythmias using ECG data acquired from adults without pacemakers, authorized in March 2020.
2026-04
PMC (NIH)
Artificial intelligence in cardiology: Hope for the future and power for the present - PMC - NIH
This review article discusses the role of AI in cardiology and lists the AI-ECG Tracker from Shenzhen Carewell Electronics Co., Ltd., as an FDA 510(k) premarket notification device for the assessment of arrhythmias using ECG data.
2020-03
Videos
Product demos, reviews, and walkthroughs for AI-ECG Tracker.
The Completely In Canal Hearing Aid Is Close To Invisible! #oddlysatisfying #rochesterny #audiology
Frequently Asked Questions
AI-ECG trackers are designed to integrate seamlessly with existing ECG platforms and Electronic Health Records (EHRs), often through web or desktop applications. They provide diagnostic support by analyzing raw ECG signals to detect patterns often missed by conventional methods, offering insights into various cardiac conditions, risk stratification, and prompting timely interventions.
Many AI-ECG trackers have obtained CE Mark certification in the EU and some have FDA clearance in the US, with cardiology having over 200 FDA-cleared AI algorithms. To ensure patient data privacy and security, these systems typically adhere to regulations like HIPAA in the US and GDPR in Europe, implementing robust safeguards for data storage, transfer, and processing.
Clinical studies often demonstrate that AI-ECG trackers can outperform traditional human interpretation in detecting certain arrhythmias and conditions, showing higher sensitivity and specificity in some cases, and significantly reducing missed diagnoses. While traditional computer interpretations can have inaccuracies, advanced AI models offer enhanced diagnostic precision by processing complex, high-dimensional data.
The cost structure for AI-ECG trackers can vary, but recent developments include the Centers for Medicare & Medicaid Services (CMS) establishing a national Medicare payment rate of $128.90 for certain AI-powered ECG analysis, effective January 1, 2025. Cost-effectiveness studies suggest that AI-ECG can be a cost-effective screening tool, especially when implemented in outpatient settings, potentially leading to long-term healthcare savings.
Known limitations of AI-ECG trackers include their reliance on large amounts of high-quality data, which can limit their accuracy for rare diseases with smaller sample sizes, and the potential for systematic bias if training data is not diverse. Some models may also exhibit a 'black box' nature, making their decision-making process difficult to interpret, and performance can vary across different clinical settings.
Numerous clinical validation studies have been conducted, demonstrating the accuracy and reliability of AI-ECG trackers for various cardiac conditions. These studies have shown high area under the curve (AUC), sensitivity, and specificity in detecting conditions like acute Occlusion Myocardial Infarction (OMI), severe arrhythmias, and low ejection fraction, often comparing performance against expert physician interpretation.
Ethical considerations for AI-ECG trackers emphasize patient data privacy, security, and consent, with robust legal frameworks like HIPAA and GDPR guiding data handling. Patients have the right to know how their medical data is used and to control access, and transparent AI development processes are crucial. Data governance frameworks are essential to ensure accountability and to address concerns about data ownership and potential algorithmic bias.
Compare AI-ECG Tracker
VS
uOmnispace.MR vs AI-ECG Tracker
uOmnispace.MR focuses on AI-powered analysis of magnetic resonance (MR) images across various specialties like cardiology, neurology, and oncology, providing advanced post-processing and segmentation. In contrast, AI-ECG Tracker specializes…
VS
AI-ECG Tracker vs EchoNext
Both AI-ECG Tracker and EchoNext are FDA-cleared AI tools that analyze ECGs for cardiac conditions, making them direct competitors. While AI-ECG Tracker focuses on a broad range of…
VS
AI-ECG Tracker vs Cardiomo
Tool A, AI-ECG Tracker, focuses on professional ECG auto-diagnosis within clinical settings, offering high-accuracy analysis of 12-lead ECG data. Tool B, Cardiomo, provides continuous, remote heart health monitoring…
VS
AI-ECG Tracker vs PMcardio
Both AI-ECG Tracker and PMcardio are highly comparable AI-powered tools designed for ECG auto-analysis and diagnosis, primarily targeting cardiology and emergency medicine. While AI-ECG Tracker emphasizes an on-premise…
Suggest an Edit →
| Last Verified: 2026-04-19 | First Added: 2026-04-19